Abecma (TSVT) is being jointly developed and commercialized in the U.S. as part of a Co-Development, Co-Promotion, and Profit Share Agreement between Bristol Myers Squibb (BMY) and 2seventy bio. Bristol Myers Squibb assumes sole responsibility for Abecma drug product manufacturing and commercialization outside of the U.S. The companies’ broad clinical development program for Abecma includes ongoing and planned clinical studies, KarMMa-2, KarMMa-3, KarMMa-9, in earlier lines of treatment for patients with multiple myeloma…Abecma generated $56M U.S. commercial revenue in the fourth quarter of 2023 and $358M for the full year, shared equally with Bristol Myers Squibb
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on TSVT:
- 2Seventy Bio, Inc. (TSVT) Q4 Earnings Cheat Sheet
- 2seventy bio and BMS Schedule FDA Panel for Abecma
- Bristol Myers and 2seventy Bio’s application for Abecma to be reviewed by FDA
- 2seventy Bio upgraded to Outperform at Leerink on acquisition potential
- 2seventy Bio upgraded to Outperform from Market Perform at Leerink